Muhonen T T, Wiklund T A, Blomqvist C P, Pyrhönen S O
Department of Radiotherapy and Oncology, Helsinki University Central Hospital, Finland.
Eur J Cancer. 1992;28A(12):1974-6. doi: 10.1016/0959-8049(92)90241-s.
28 patients (26 with breast cancer and 2 with colon cancer) received mitomycin, mitoxantrone and methotrexate (MMM). Half the patients had grade III-IV leukopenia and 29% had grade III-IV thrombocytopenia. The median time of recovery to WHO grade 0 was 62 and 128 days, respectively. Thrombocytopenia and leukopenia were more frequent and longer lasting after the three-drug part of the therapy, which suggests a critical role for mitomycin in this toxicity.
28名患者（26名乳腺癌患者和2名结肠癌患者）接受了丝裂霉素、米托蒽醌和甲氨蝶呤（MMM）治疗。一半患者出现III-IV级白细胞减少，29%患者出现III-IV级血小板减少。恢复至WHO 0级的中位时间分别为62天和128天。在三联药物治疗阶段后，血小板减少和白细胞减少更为常见且持续时间更长，这表明丝裂霉素在这种毒性反应中起关键作用。
